

Original Article

Antibacterial, anti-inflammatory, and anti-osteoclastogenesis roles of allicin in periodontitis

Xiaoxu Guan, Yi Zhou, Hui Chen, Chaowei Wang, Huiming Wang

Affiliated Hospital of Stomatology, Medical College, Zhejiang University, Yan'an Road 395, Hangzhou 310000, People's Republic of China

Received October 7, 2017; Accepted May 1, 2018; Epub July 15, 2018; Published July 30, 2018

Abstract: Periodontitis is an infectious inflammatory immune disease. Allicin, because of its antibacterial, anti-inflammatory and immunomodulation properties, appears to be a promising drug for treating periodontitis. In this study, the antimicrobial activity of allicin against *Porphyromonas gingivalis* (*P. gingivalis*) and its effects on inflammatory cytokine expression in experimental periodontitis and osteoclast activity *in vitro* were investigated. Allicin inhibited *P. gingivalis* growth, with a minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of 4 mg/l and 8 mg/l, respectively. Allicin showed inhibitory effects on *P. gingivalis* biofilm formation, with a minimum biofilm inhibition concentration (MBIC₅₀/MBIC₉₀) of 4 mg/l and 16 mg/l, respectively, and affected the viability of 1-day-old biofilms with a minimum biofilm reduction concentration (MBRC₅₀) of 32 mg/l. Confocal laser scanning microscopy (CSLM) revealed that treatment with 32 mg/l allicin resulted in a lower bacteria number, fewer live bacteria, and a thinner biofilm. In gingivomucosal tissues around first right molar teeth undergoing ligature-induced periodontitis, allicin substantially inhibited periodontal destructive cytokines, including TNF- α , IL-1 β , IL-6, INF- γ , and IL-12, but promoted protective cytokines such as IL-4 and IL-10. By affecting the cytokine framework and the secretion of M-CSF and RANKL from osteoblasts, allicin suppressed osteoclastogenesis by modulating the RANK-RANKL system, as demonstrated by a decrease in NF- κ B p65 levels. These results suggested that allicin is a potential natural product for treating periodontitis.

Keywords: Periodontitis, *Porphyromonas gingivalis*, allicin, growth, biofilm, osteoclastic activity

Introduction

Periodontitis is an inflammatory disorder that continues to be a major oral health problem worldwide [1]. It is caused by the infection with Gram-negative organisms, particularly *Porphyromonas gingivalis* (*P. gingivalis*), which is one of the most essential factors in periodontitis. The virulence factors produced by *P. gingivalis* can cause abnormal host defences [1, 2]. Activated immune cells secrete an abundance of inflammatory cytokines, thereby triggering an aberrant host immune reaction and eventually cause progressive periodontal tissue damage [3]. Among these inflammatory cytokines, TNF- α , INF- γ , IL-1, IL-4, IL-6 and IL-12 have been shown to be involved in the pathogenesis of periodontitis [3]. In addition to the control of invasive pathogens at the cost of periodontal tissue damage via induction of a cellular immune reaction, these factors could also acti-

vate the receptor activator of nuclear factor- κ B (NF- κ B) (RANK)-RANKL system, the stimulation of which could induce elevated resorption of alveolar bone [4].

The treatment for periodontitis generally includes mechanical debridement, periodontal surgery and antibacterial agents [5]. Mechanical debridement is performed to remove dental plaque, but the host's unique immune reaction in periodontitis is ignored [3]. Periodontal surgery is not the only non-ideal therapeutic strategy for advanced periodontitis, but it also presents a financial consideration in developing countries. Regarding antibiotics, undesirable side effects, such as drug resistance, vomiting, and tooth staining, limit their clinical application [6]. Hence, alternative products from natural plants used as traditional medicines are considered as alternatives. Allicin may be a promising anti-microorganism agent.

Allicin for periodontitis treatment

Allicin, a garlic extract that is known for the production of organosulfur compounds, exhibits varying biological and pharmacological functions. The chemical compound not only acts against microbial infections but also shows cardioprotective, anti-cancerogenic, and anti-inflammatory activity [7-10]. Although no studies have described the role of allicin in treating periodontitis, several researchers have shown that allicin inhibits the adhesion, growth and biofilm formation of bacteria, including *Escherichia*, *Salmonella*, *Staphylococcus*, *Streptococcus*, *Klebsiella*, *Proteus*, *Clostridium*, and *Mycobacterium* [11]. In addition, by regulating systemic inflammatory cytokines such as TNF- α , INF- γ , IL-1, IL-4, IL-6 and IL-12, allicin could control the body's inflammatory response [4, 12-16]. Decreased expression of these pro-inflammatory factors is helpful in relieving NF- κ B activation and osteoclastic activity [4]. In addition, with mechanisms including modulation of cytokine secretion as described above, immunoglobulin production, and macrophage activation, allicin can regulate the stability of the immune system by stimulating macrophages, lymphocytes, natural killer (NK) cells, and other types of immune cells [4, 12-16].

Interestingly, all biological effects shown by allicin are beneficial for periodontitis treatment. It is thus reasonable to hypothesize that allicin may be a potential natural product for the treatment of periodontitis. In this study, the antimicrobial activity of allicin against the growth and biofilm formation of *P. gingivalis*, inflammatory cytokine levels in experimental periodontitis after allicin washing, and *in vitro* osteoclastogenesis after allicin treatment were examined to demonstrate that allicin is a promising drug for periodontitis treatment.

Materials and methods

Chemicals, bacterial strain, growth medium and growth conditions

Allicin was supplied by Shanghai Guangrui Bioscience Inc., Shanghai, China. All other reagents, unless otherwise stated, were purchased from Sigma (St. Louis, MO, USA). *P. gingivalis* (ATCC33277) was obtained from the State Key Laboratory of Oral Disease (Chengdu, Sichuan, China). TSB-yeast extract medium for culturing *P. gingivalis* was supplemented with 0.02 μ g/ml menadione, 0.05% cysteine hydrochloride, 0.02% potassium nitrate, and 5 μ g/ml

hemin. *P. gingivalis* subcultures were incubated in an anaerobic chamber containing 10% H₂, 5% CO₂ and 85% N₂ at 37°C.

Minimal inhibitory (MIC) and minimal bactericidal concentration (MBC) determination

The assays were performed by a modification of that described by Cutler and Wilson [17]. For MIC measurement, two-fold serial dilutions of allicin, ranging from 0.5 mg/l to 16 mg/l, were prepared at volumes of 100 μ l/well in 96-well plates. Then, a 20- μ l bacterial cell suspension was added to each well at a final concentration of 1×10^6 colony-forming units (CFU)/ml. After the cells were subcultured for 1 d, the MIC was defined as the lowest concentration at which no visible bacterial growth against a black background was observed. Similarly, to determine the MBC, we prepared aliquots of bacterial cell suspension in the 96-well plates with an allicin concentration greater than the MIC. The MBC was defined as the lowest concentration at which no surviving cells were detected on the agar.

Time-kill curve

A time-kill kinetic curve was obtained as previously described using the microdilution method [17, 18]. The allicin concentrations used in the assay corresponded to 1/2 the MIC, MIC and MBC. At specified time intervals (0 min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 18 h and 24 h), samples were serially diluted, re-plated onto new medium and counted with a colony counter (Synbiosis Acolyte 7510; Microbiology International, MD, USA). The curve was then drawn by plotting log₁₀ CFU/ml versus time (h).

Biofilm susceptibility assay

Aliquots of bacterial suspension, as described above, were subcultured in an anaerobic environment at 37°C for 1 d. After treatment with allicin concentrations ranging from 0.5 mg/l to 32 mg/l, samples were washed with PBS, fixed with methanol for 15 min, stained with 0.1% (w/v) crystal violet for 5 min and rinsed with ddH₂O until no colour was visible in the control well. Aliquots of 95% ethanol were added for 30 min to dissolve the crystals. OD values (A₅₉₀) were measured by a Microplate Reader (Bio-Rad, Hercules, CA, USA). The minimum biofilm inhibition (MBIC₅₀/MBIC₉₀) was defined as the lowest concentration at which 50% or 90% of

Allicin for periodontitis treatment

Table 1. Susceptibility of *Porphyromonas gingivalis* to the antimicrobial reagent allicin

<i>P. gingivalis</i> (ATCC33277)	MIC	MBC	MBIC ₅₀	MBIC ₉₀	MBRC ₅₀
Allicin (mg/L)	4	8	4	16	32




Figure 1. The kinetic killing effect of allicin on *P. gingivalis* in planktonic cell cultures. Data are presented as the mean \pm SD ($n > 3$). CFU, colony-forming units.

biofilm formation was inhibited. To determine the minimum biofilm reduction concentration (MBRC₅₀), culture medium with high allicin concentrations was added to 1-day-old biofilm and incubated for an additional 24 h. By assessing OD values at A₅₉₀, the MBRC₅₀ was calculated as the lowest concentration that could reduce the formation of biofilm by $\geq 50\%$.

Confocal laser scanning microscopy (CLSM)

A one-day-old biofilm was formed on Lab-Tek® Chamber Permanox™ slides (Nagle Nunc International, NY, USA). Culture medium containing 32 mg/l allicin (MBRC₅₀) was added to the wells and incubated for one additional day. Slides were stained for 15-20 min in a dark room with the LIVE/DEAD® BacLight™ Bacterial Viability Kit (Molecular Probes Inc., OR, USA). The live/dead cells were viewed under a Leica TCS SP2 microscope (Leica TCS SP2; Leica Microsystems, Wetzlar, Germany).

Periodontitis model establishment and allicin treatment

Animal care and experiments were performed in accordance with guidelines issued by the

Institutional Animal Care and Use Committee, Zhejiang University, Hangzhou, China. Animals were randomly divided into four groups: sham ($n = 8$), periodontitis ($n = 9$), periodontitis + allicin treatment at the MIC ($n = 9$),

and periodontitis + allicin treatment at the MBC ($n = 9$). To establish a periodontitis model, Sprague-Dawley rats (374 ± 45 g body weight) were anesthetized with 4% isoflurane vapour, and a sterile 28-gauge wire ligature was tied around the cervical portion of the right first molar [19]. The experimental rats were monitored daily to ensure the presence of the ligature. After ligature induced-periodontitis models were established, for allicin treating, animals were anesthetized with 4% isoflurane vapour, then injected with 2 ml PBS with or without allicin (4 mg/l or 8 mg/l) on the palatal gingiva of the first molars, as previously described [20]. At seven days, gingivomucosal tissues surrounding the molar teeth were harvested for further experiments, including cytokine analysis and western blotting.

Gingivomucosal cytokine analysis

The digestion solution for the collected gingivomucosal tissues included 50 μ g/ml gentamycin, 500 U/ml collagenase, 100 μ g/ml zwittergent-12, 10 mM HEPES buffer, and 100 μ g/ml bovine serum albumin in RPMI 1640 [21]. The samples were minced, weighed, digested, sonicated, and centrifuged. The TNF- α , IL-1 β , IL-4, IL-6, IL-10, INF- γ and IL-12 levels in supernatants were determined using a commercial colorimetric kit (R&D Systems Inc., USA). All cytokine concentrations are expressed as pg/mg tissue.

Western blotting

The protein samples collected from gingivomucosal tissues were solubilized in lysis buffer, as previously described [22]. To measure NF- κ B p65 levels from nuclear fraction of the harvested samples, we separated the samples on 8% SDS-PAGE gels, transferred them onto polyvinylidene difluoride membranes, blocked them in 5% non-fat milk for 1 h and incubated them with specific primary antibodies overnight at 4°C. After the samples were incubated with a horseradish peroxidase-conjugated secondary antibody (1:2000) for 1 h at room temperature, protein bands were visualized with




Figure 2. Confocal laser scanning microscopy images of *P. gingivalis* biofilms after allicin treatment. Dead bacteria are stained red, whereas live bacteria are stained green using a LIVE/DEAD[®] BacLight[™] Bacterial Viability Kit. A. Allicin-untreated group (Control; magnification: $\times 400$). B. Allicin-treated group (32 mg/L; magnification: $\times 400$). C. 0.05% chlorhexidine-treated group (Positive control group; magnification: $\times 400$).

enhanced chemiluminescence reagents using a Pico kit. The intensities of bands were assessed by Scion Image Beta 4.0.2 software (Scion Corporation, MD, USA).

Cell culture, allicin treatment and in vitro osteoclastogenesis assay

Osteoblast and osteoclast precursor isolation and co-culture: Osteoblasts and bone marrow cells were isolated from the tibias and femurs of the experimental Sprague-Dawley rats, as our previous study published in “Bone” described [23]. The adherent bone marrow macrophages (BMMs) were chosen as osteoclast precursors. BMMs (2×10^4 , passage 2-4) were cultured in 24-well plates with α -MEM medium + 10% FBS. Transwell chambers (pore diameter: 3 μ m; Corning) that were cultivated with 1×10^4 osteoblasts were placed into the 24-well plates. The co-culture systems were then treated with 4 or 8 mg/l allicin for 4 days.

Enzyme-linked immunosorbent assay (ELISA): The supernatants were collected from co-cultured medium on day 4. RANKL and M-CSF levels were quantified using ELISA kits (R&D Systems Inc., USA). The cytokine concentrations are presented as the amount (pg) of each cytokine per ml of supernatant.

Tartrate resistant acid phosphatase (TRAP) staining: Cells were fixed in a solution of 4% formaldehyde for 30 sec, incubated in TRAP staining solution for 1 h at 37°C, rinsed in de-ionized water, air-dried and evaluated microscopically. Eight fields under a $\times 4$ objective were randomly selected for each well. The numbers of TRAP+ multinucleate (at least three nuclei) cells (MNCs) were counted and recorded as the number of osteoclasts.

Statistical analysis

All data were collected from triplicate experiments reproduced at least three times. Data

Allicin for periodontitis treatment




Figure 3. The ratios of live bacteria and the average thicknesses of *P. gingivalis* biofilms treated with allicin. A. The percent of live bacteria was significantly decreased after allicin treatment. B. The thickness of biofilms was dramatically reduced after allicin treatment. Data are presented as the mean \pm SD ($n > 3$). * $P < 0.05$ vs Allicin-untreated controls.

are expressed as the mean \pm standard deviation (SD). The statistical analysis was conducted using Student's t-test or ANOVA followed by Dunnett's test or the Student-Newman-Keuls test. A value of $P < 0.05$ was considered statistically significant.

Results

Antibacterial activity of allicin against P. gingivalis in planktonic culture

Allicin showed an inhibitory effect on *P. gingivalis* with a MIC of 4 mg/l. An allicin concentration of 8 mg/l could completely kill *P. gingivalis* in planktonic culture (Table 1). To dynamically assess the antimicrobial activity of allicin, time-kill kinetic studies were further performed. As presented in Figure 1, the cell-killing effects exhibited by allicin on *P. gingivalis* were time- and concentration-dependent. When the drug level reached 8 mg/l (MBC), the time-kill curve showed a trend similar to that observed with 0.05% chlorhexidine (Figure 1).

Inhibitory/destructive effects of allicin on P. gingivalis biofilm

Allicin could inhibit biofilm formation by *P. gingivalis*, with an MBIC₅₀ of 4 mg/l and an MBIC₉₀ of 16 mg/l (Table 1). As the drug levels increased, 32 mg/l of allicin (MBRC₅₀) could suppress the viability of previously formed *P. gingivalis* biofilms.

To further ensure the effects of allicin on previously-formed *P. gingivalis* biofilms, we conduct-

ed CLSM on 1-day-old biofilms (Figure 2). Compared to the treatment provided to the periodontitis group, 32 mg/l (MBRC₅₀) allicin treatment resulted in a lower cell number, fewer live cells (Figures 2 and 3A; * $P < 0.05$) and more dead cells, although this favourable effect was not as apparent when compared to the 0.05% chlorhexidine-treated group. In addition, allicin-treated biofilms were also less uniform than those in the drug-untreated group (Figure 2).

The biofilm thicknesses in each group were measured by CLSM. In the control group, the thickness was $43.1 \pm 5.3 \mu\text{m}$. However, the biofilm was thinner in the allicin-treated group ($27.4 \pm 4.1 \mu\text{m}$; Figure 3B; * $P < 0.05$). The results suggested that allicin not only killed *P. gingivalis* within the biofilm but also disrupted the environment of *P. gingivalis* by disintegrating the biofilm.

Allicin-induced modulation of inflammatory cytokine expression and NF- κ B p65 levels in gingivomucosal tissues around first right molar teeth undergoing ligature-induced periodontitis

As shown in Table 2, destructive cytokines, including TNF- α , IL-1 β , INF- γ , IL-6 and IL-12, exhibited dramatically elevated levels in experimental rat periodontitis on day 4 (* $P < 0.05$). Although allicin was unable to revert these cytokine levels to a normal status, they were much lower in the allicin-treated group (# $P < 0.05$). It is worth noting that allicin not only significantly inhibited the inflammatory cytokine levels but also showed the ability to promote the secretion of IL-4 and IL-10 (# $P < 0.05$), two cytokines that protect against periodontitis. These data thus suggested that allicin could change the cytokine framework in periodontitis from a "destructive" to a "protective" pattern. As the drug concentration increased (8 mg/l, MBC), this favourable effect became more apparent (& $P < 0.05$).

To determine whether allicin could relieve the abnormal osteoclastic activity that occurs in

Allicin for periodontitis treatment

Table 2. Effects of allicin on gingivomucosal cytokine expressions levels

Cytokines (pg/mg GT)	Sham	PD	PD + Allicin (4 mg/L)	PD + Allicin (8 mg/L)
TNF- α	39.27 \pm 4.35	85.14 \pm 7.8*	62.45 \pm 8.12 [#]	47.23 \pm 4.87 ^{&}
IL-1 β	21.56 \pm 2.56	41.34 \pm 4.96*	31.42 \pm 2.72 [#]	27.47 \pm 2.87
INF- γ	12.3 \pm 1.25	32.2 \pm 1.56*	19.4 \pm 2.01 [#]	13.3 \pm 1.23 ^{&}
IL-4	5.14 \pm 0.68	5.67 \pm 0.97	5.38 \pm 0.54	9.41 \pm 1.02 ^{&}
IL-6	3.21 \pm 0.22	10.25 \pm 0.67*	7.21 \pm 0.82 [#]	3.87 \pm 0.41 ^{&}
IL-10	11.23 \pm 1.23	10.37 \pm 1.04	17.34 \pm 1.89 [#]	23.5 \pm 3.12 ^{&}
IL-12	0.57 \pm 0.041	0.89 \pm 0.12*	0.54 \pm 0.061 [#]	0.52 \pm 0.038

* $P < 0.05$ vs Sham without periodontitis group. [#] $P < 0.05$ vs periodontitis group. [&] $P < 0.05$ vs periodontitis and 4 mg/L allicin treated group. GT, gingivomucosal tissue, PD, periodontitis.




Figure 4. Effects of allicin (4 or 8 mg/l) on NF- κ B p65 expression in gingivomucosal tissues around first right molar teeth undergoing ligature-induced periodontitis. Data are presented as the mean \pm SD (n=8-9). * $P < 0.05$ vs Sham without ligature induction of periodontitis. [#] $P < 0.05$ vs ligature-induced periodontitis group. [&] $P < 0.05$ vs ligature-induced periodontitis and 4 mg/l allicin-treated group. PD, periodontitis.

Table 3. Inhibitory effects of allicin on osteoblasts secretion of the cytokines M-CSF and RANKL cytokines

	Control	Allicin (4 mg/L)	Allicin (8 mg/L)
RANKL (pg/ml)	17.47 \pm 1.87	11.35 \pm 1.34*	6.43 \pm 1.32 [#]
M-CSF (pg/ml)	39.53 \pm 4.23	19.4 \pm 2.03*	12.4 \pm 1.54 [#]

* $P < 0.05$ vs Control group. [#] $P < 0.05$ vs 4 mg/L allicin treated group.

periodontitis, we detected the level of NF- κ B p65, a key factor in the RANK-RANKL system. Western blotting showed that allicin inhibited the expression of NF- κ B p65 in a concentration-dependent manner (**Figure 4**; [#] $P < 0.05$). The reduction of inflammatory cytokine levels by allicin may cause inhibition of osteoclastic activity.

Inhibitory effects of allicin on osteoclastogenesis via suppression of M-CSF and RANKL production by osteoblasts in vitro co-culture

Regulation of osteoclastogenesis requires the RANK-RANKL system, which involves cell-ce-

ll contacts (osteoblasts/stromal cells and osteoclastic precursors) and secreted soluble cytokines (RANKL and M-CSF). To further examine the underlying mechanisms of allicin on osteoclastogenesis, osteoblasts and osteoclastic precursors were co-cultured *in vitro*. The ELISA data indicated that allicin could inhibit secretion of M-CSF and RANKL cytokines by osteoblasts in a concentration-dependent manner (**Table 3**; [#] $P < 0.05$). TRAP staining revealed that due to the dramatically reduced levels of M-CSF and RANKL, osteoclast formation was significantly decreased in allicin-treated groups; this inhibitory effect was also concentration-dependent (**Figure 5**; ^{*} $P < 0.05$).

Discussion

Periodontitis is not only a chronic infectious disease but also an inflammatory immune disorder. Due to increased bacterial resistance to antibiotics and an increasing focus on the unique immune response in periodontitis, considerable concern exists regarding the development of other antibacterial agents. These antibacterial agents should not only have few side effects but should also be able to control the abnormal immune reaction that occurs in periodontitis. The benefits of garlic on human health have been previously demonstrated. Allicin, a garlic extract, has been shown to

Alicin for periodontitis treatment




Figure 5. Effects of alicin on osteoclastogenesis of osteoclast precursors in vitro coculture. Data are presented as the mean \pm SD ($n > 3$). * $P < 0.05$ vs alicin-untreated controls. MNCs: multinucleate cells. TRAP: tartrate resistant acid phosphatase staining.

have an antibacterial property [11]. It also has been proposed as a promising natural product for maintaining the stability of the immune system [4, 12-16]. Hence, local application of alicin may be a helpful for the treatment of periodontitis.

P. gingivalis is regarded as one of the most important microorganisms in the occurrence and disease process of periodontitis [3]. Alicin not only affects the survival of *P. gingivalis*, but also inhibits and kills other bacteria, including *Escherichia*, *Salmonella*, *Streptococcus*, *Proteus*, *Clostridium*, *Mycobacterium* and *Helicobacter* species [11]. Alicin thus has a wide spectrum of antibacterial activity. Periodontitis represents the infectious outcome of many Gram-negative bacteria. The favourable actions of alicin on some of these Gram-negative species are helpful in treating periodontitis, and these bacteria species should be clarified in further investigations.

Bacteria that generally reside in the mouth form dental plaques comprising a highly organized microorganism community [24]. Bacteria in these plaques are less susceptible to antimicrobial agents. To inhibit new biofilms or destroy previously-formed biofilms is thus of great importance for anti-periodontitis drugs. In this study, we showed that alicin exhibited inhibitory effects on *P. gingivalis* biofilm formation and 1-day-old biofilm with a $MBIC_{50}$ of 4 mg/l, $MBIC_{90}$ of 16 mg/l, and $MBRC_{50}$ of 32 mg/l. CLSM indicated that the action of alicin on biofilm is a result of bacterial growth inhibition and killing effects because the biofilm thickness in the alicin-treated group was significantly decreased, and the number of red-stained cells (dead bacteria) was dramatically

increased. In contrast, damage to the organized microstructure in *P. gingivalis* biofilm also serves as positive feedback for alicin action because the disintegrated biofilm is more vulnerable to antimicrobial agents.

In addition to controlling bacterial infection, immunomodulation and inflammatory regulation need to be investigated for periodontitis treatment in the future. This could be examined by dynamic regulation of proinflammatory cytokines such as TNF- α , IL-1 β , INF- γ , IL-6 and IL-12.

TNF- α , which is highly expressed in gingival crevicular fluid, is positively associated with periodontal tissue damage [25-27]. In addition to directly promoting RANKL expression, TNF- α acts as an important chemotactic cytokine and inducer and could stimulate the production of other pro-inflammatory immune cytokines, including IL-1 β , IL-6 and INF- γ [25-27]. INF- γ exerts positive feedback and could further promote the expression of TNF- α [28]. All of these cytokines and chemokines have been shown to be highly expressed in periodontitis, causing rapid cell migration, elevated osteoclastogenesis by promoting RANKL expression, and increased bone absorption [3, 27].

These chemokines and cytokines not only trigger an acute inflammatory response, but some are also involved in periodontitis-related abnormal immune reactions. IL-6 is associated with B-cell differentiation and antibody production [29]. The autoantibodies produced by B cells, including collagen, vimentin, and actin, serve as immunogens and will result in aggressive periodontitis [30]. The deletion of B-cells is helpful in preventing bone loss in mice that suffer from *P. gingivalis* infection [31, 32]. In addi-

tion, INF- γ and IL-12 are mainly associated with T-cell activation [28, 33]. Th1 cell stimulation not only induces an abnormal adaptive immune response and progressive periodontal damage but is also a stimulus for RANKL accumulation and alveolar bone loss [33].

Interestingly, by inhibiting these destructive cytokines, allicin exhibits phytotherapy for periodontitis treatment. Moreover, allicin can increase levels of IL-4 and IL-10, which are two cytokines that protect against periodontitis [34-37]. The upregulation of IL-10 may cause downregulation of the proinflammatory cytokines TNF- α , IL-1 β , INF- γ , and IL-6 and increase the body's resistance to *P. gingivalis*, preventing osteoclastogenesis via inhibition of the RANK-RANKL system and reducing the severity of periodontitis [38, 39]. IL-4 also presents anti-inflammatory properties due to its capacity to inhibit INF- γ expression and Th1 cell stimulation [36, 37]. Hence, by changing the cytokine framework from a destructive pattern into a protective mode, allicin could relieve tissue damage during the periodontitis.

Alteration of the cytokine framework is beneficial for controlling osteoclastic activity. Osteoclastogenesis requires cell-cell contacts with osteoblasts/stromal cells and secreted soluble cytokines including RANKL and M-CSF [4]. Our *in vitro* data showed that allicin indirectly affected osteoclasts by influencing the production of RANKL and M-CSF. Therefore, osteoblasts or other stromal cells may also be responsible for allicin-induced inhibition of osteoclastic activity.

Thus, daily intake of allicin or mouth washing may to some extent be beneficial in treating or preventing periodontitis.

Acknowledgements

This study was supported by the National Science Foundation of China (grant No. 81-400480).

Disclosure of conflict of interest

None.

Address correspondence to: Yi Zhou and Huiming Wang, Department of Oral Implantation, Affiliated Hospital of Stomatology, Medical College, Zhejiang University, Yan'an Road 395, Hangzhou 310000,

People's Republic of China. Tel: +86-0571-87-217419; Fax: +86-0571-87217419; E-mail: zyuth-scsa@zju.edu.cn (YZ); hmwang1960@hotmail.com (HMW)

References

- [1] Teles R, Teles F, Frias-Lopez J, Paster B, Haffajee A. Lessons learned and unlearned in periodontal microbiology. *Periodontol 2000* 2013; 62: 95-162.
- [2] Nakayama K. Molecular genetics of porphyromonas gingivalis: gingipains and other virulence factors. *Curr Protein Pept Sci* 2003; 4: 389-395.
- [3] Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, Hernández M, Gamonal J. Host response mechanisms in periodontal diseases. *J Appl Oral Sci* 2015; 23: 329-355.
- [4] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003; 423: 337-342.
- [5] Pereira AL, Cortelli SC, Aquino DR, Franco GC, Cogo K, Rodrigues E, Costa FO, Holzhausen M, Cortelli JR. Reduction of salivary arginine catabolic activity through periodontal therapy. *Quintessence Int* 2012; 43: 777-787.
- [6] Palombo EA. Traditional medicinal plant extracts and natural products with activity against oral bacteria: potential application in the prevention and treatment of oral diseases. *Evid Based Complement Alternat Med* 2011; 2011: 680354.
- [7] Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. *Nutr Res Rev* 2009; 22: 39-48.
- [8] Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. *Nutrients* 2013; 5: 3646-3683.
- [9] Khatua TN, Adela R, Banerjee SK. Garlic and cardioprotection: insights into the molecular mechanisms. *Can J Physiol Pharmacol* 2013; 91: 448-458.
- [10] Fridman S, Sinai T, Zilberg D. Efficacy of garlic based treatments against monogenean parasites infecting the guppy (*Poecilia reticulata* (Peters)). *Vet Parasitol* 2014; 203: 51-58.
- [11] Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of *Helicobacter pylori* by garlic extract (*Allium sativum*). *FEMS Immunol Med Microbiol* 1996; 13: 273-277.
- [12] Kim SR, Jung YR, An HJ, Kim DH, Jang EJ, Choi YJ, Moon KM, Park MH, Park CH, Chung KW, Bae HR, Choi YW, Kim ND, Chung HY. Anti-wrinkle and anti-inflammatory effects of active garlic components and the inhibition of MMPs via NF-kappaB signaling. *PLoS One* 2013; 8: e73877.

Allicin for periodontitis treatment

- [13] Spelman K, Burns J, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. *Altern Med Rev* 2006; 11: 128-150.
- [14] You S, Nakanishi E, Kuwata H, Chen J, Nakasone Y, He X, He J, Liu X, Zhang S, Zhang B, Hou DX. Inhibitory effects and molecular mechanisms of garlic organosulfur compounds on the production of inflammatory mediators. *Mol Nutr Food Res* 2013; 57: 2049-2060.
- [15] Fu E, Tsai MC, Chin YT, Tu HP, Fu MM, Chiang CY, Chiu HC. The effects of diallyl sulfide upon *Porphyromonas gingivalis* lipopolysaccharide stimulated proinflammatory cytokine expressions and nuclear factor-kappa B activation in human gingival fibroblasts. *J Periodontol Res* 2015; 50: 380-388.
- [16] Ho CY, Weng CJ, Jhang JJ, Cheng YT, Huang SM, Yen GC. Diallyl sulfide as a potential dietary agent to reduce TNF-alpha- and histamine-induced proinflammatory responses in A7r5 cells. *Mol Nutr Food Res* 2014; 58: 1069-1078.
- [17] Cutler RR, Wilson P. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant *Staphylococcus aureus*. *Br J Biomed Sci* 2004; 61: 71-74.
- [18] Sharma S, Khan IA, Ali I, Ali F, Kumar M, Kumar A, Johri RK, Abdullah ST, Bani S, Pandey A, Suri KA, Gupta BD, Satti NK, Dutt P, Qazi GN. Evaluation of the antimicrobial, antioxidant, and anti-inflammatory activities of hydroxychavicol for its potential use as an oral care agent. *Antimicrob Agents Chemother* 2009; 53: 216-222.
- [19] Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, Bezouglaia O, Dry SM, Tetradis S. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. *J Bone Miner Res* 2011; 26: 1871-1882.
- [20] Kador PF, O'Meara JD, Blessing K, Marx DB, Reinhardt RA. Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats. *J Periodontol* 2011; 82: 926-933.
- [21] Niederman R, Westernoff T, Lee C, Mark LL, Kawashima N, Ullman-Culler M, Dewhirst FE, Paster BJ, Wagner DD, Mayadas T, Hynes RO, Stashenko P. Infection-mediated early-onset periodontal disease in P/E-selectin-deficient mice. *J Clin Periodontol* 2001; 28: 569-575.
- [22] Di Paola R, Briguglio F, Paterniti I, Mazzon E, Oteri G, Militi D, Cordasco G, Cuzzocrea S. Emerging role of PPAR-beta/delta in inflammatory process associated to experimental periodontitis. *Mediators Inflamm* 2011; 2011: 787159.
- [23] Zhou Y, Guan X, Liu T, Wang X, Yu M, Yang G, Wang H. Whole body vibration improves osseointegration by up-regulating osteoblastic activity but down-regulating osteoblast-mediated osteoclastogenesis via ERK1/2 pathway. *Bone* 2015; 71: 17-24.
- [24] Peterson BW, He Y, Ren Y, Zerdoum A, Libera MR, Sharma PK, van Winkelhoff AJ, Neut D, Stoodley P, van der Mei HC, Busscher HJ. Viscoelasticity of biofilms and their recalcitrance to mechanical and chemical challenges. *FEMS Microbiol Rev* 2015; 39: 234-245.
- [25] Musacchio E, Valvason C, Botsios C, Ostuni F, Furlan A, Ramonda R, Modesti V, Sartori L, Punzi L. The tumor necrosis factor- α -blocking agent infliximab inhibits interleukin 1 β (IL-1 β) and IL-6 gene expression in human osteoblastic cells. *J Rheumatol* 2009; 36: 1575-1579.
- [26] Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. *Autoimmun Rev* 2009; 8: 538-542.
- [27] Preshaw PM. Host response modulation in periodontics. *Periodontol* 2000 2008; 48: 92-110.
- [28] Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. *J Clin Invest* 2007; 117: 122-132.
- [29] Cronstein BN. Interleukin-6—a key mediator of systemic and local symptoms in rheumatoid arthritis. *Bull NYU Hosp Jt Dis* 2007; 65 Suppl 1: S11-15.
- [30] Koutouzis T, Haber D, Shaddox L, Aukhil I, Wallet SM. Autoreactivity of serum immunoglobulin to periodontal tissue components: a pilot study. *J Periodontol* 2009; 80: 625-633.
- [31] Donati M, Liljenberg B, Zitzmann NU, Berglundh T. B-1a cells and plasma cells in periodontitis lesions. *J Periodontol Res* 2009; 44: 683-688.
- [32] Han X, Lin X, Seliger AR, Eastcott J, Kawai T, Taubman MA. Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. *Oral Microbiol Immunol* 2009; 24: 190-196.
- [33] Repeke CE, Ferreira SB Jr, Claudino M, Silveira EM, de Assis GF, Avila-Campos MJ, Silva JS, Garlet GP. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice. *Bone* 2010; 46: 1122-1130.
- [34] Sasaki H, Okamatsu Y, Kawai T, Kent R, Taubman M, Stashenko P. The interleukin-10 knockout mouse is highly susceptible to *Porphyromonas gingivalis*-induced alveolar bone loss. *J Periodontol Res* 2004; 39: 432-441.
- [35] Lappin DF, MacLeod CP, Kerr A, Mitchell T, Kinane DF. Anti-inflammatory cytokine IL-10

Allicin for periodontitis treatment

- and T cell cytokine profile in periodontitis granulation tissue. *Clin Exp Immunol* 2001; 123: 294-300.
- [36] Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. *Cytometry A* 2008; 73: 975-983.
- [37] Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. *Nat Rev Immunol* 2009; 9: 811-816.
- [38] Hodge G, Hodge S, Han P. *Allium sativum* (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease. *Cytometry* 2002; 48: 209-215.
- [39] Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. *Cancer Immunol Res* 2014; 2: 194-199.